Nausea and Vomiting in the Cancer Patient

Abstract

Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curable treatments. Despite the availability of more than 20 different antiemetics, nausea and vomiting in cancer patients remain problematic and continue to pose tremendous challenges to practicing oncologists.

Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966–2973.PubMed

52.

Stephens SH, Silvey VL, Wheeler RH. A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin. Cancer (Phila) 1990;66:443–446.PubMed